{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T13:43:18Z","timestamp":1785850998544,"version":"3.56.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"7","funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005002","name":"California Department of Public Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"California Health and Safety","award":["103885"],"award-info":[{"award-number":["103885"]}]},{"name":"Centers for Disease Control and Prevention\u2019s"},{"name":"National Program of Cancer Registries","award":["1NU58DP007156"],"award-info":[{"award-number":["1NU58DP007156"]}]},{"name":"National Cancer Institute\u2019s Surveillance, Epidemiology and End Results Program","award":["HHSN261201800032I"],"award-info":[{"award-number":["HHSN261201800032I"]}]},{"DOI":"10.13039\/100005595","name":"University of California","doi-asserted-by":"publisher","award":["HHSN261201800015I"],"award-info":[{"award-number":["HHSN261201800015I"]}],"id":[{"id":"10.13039\/100005595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006034","name":"University of Southern California","doi-asserted-by":"publisher","award":["HHSN261201800009I"],"award-info":[{"award-number":["HHSN261201800009I"]}],"id":[{"id":"10.13039\/100006034","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001808","name":"Public Health Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001808","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100023065","name":"State of California","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100023065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004824","name":"Department of Public Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004824","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To examine cancer risk associated with Janus kinase inhibitors (JAKis) and biological DMARDs (bDMARDs) in patients with RA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Case\u2013control study of patients with RA age 65\u2009years or older in the US Surveillance, Epidemiology, and End Results (SEER)-Medicare database during 2014\u20132019. Cases were individuals with a first cancer diagnosed in SEER registries (N\u2009=\u200912\u2009463). Cancer-free controls (N\u2009=\u200938\u2009345) were Medicare beneficiaries residing in SEER areas. Exposure to JAKis, tumour necrosis factor inhibitors (TNFis) and other bDMARDs was ascertained using prescription claims. Logistic regression was used to estimate adjusted odds ratios (ORs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>1.9% of cases and 2.0% of controls were prescribed a JAKi. Among patients prescribed a JAKi, the median duration of documented exposure was 1.8\u2009years. Overall cancer risk was not associated with exposure to JAKis (adjusted OR 1.04, 95% CI 0.87\u20131.26), TNFis (0.98, 0.92\u20131.05) or other bDMARDs (0.98, 0.90\u20131.07). However, JAKi exposure was associated with significantly increased risk of lung cancer (OR 1.40, 95% CI 1.06\u20131.87), especially in males (2.12, 1.14\u20133.94) and with &amp;gt;2\u2009years of JAKi exposure (1.52, 1.01\u20132.28). Among females, JAKi exposure was associated with lower risk of breast cancer (OR 0.62, 95% CI 0.39\u20130.97).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Among older adults with RA, JAKi exposure over a median of 1.8\u2009years was not associated with an overall increase in cancer risk. However, lung cancer risk was elevated, supporting clinical caution in prescribing this medication class to smokers. Further research is needed to understand the role of the JAK\/STAT pathway in cancer.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf092","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T16:34:22Z","timestamp":1739205262000},"page":"4172-4180","source":"Crossref","is-referenced-by-count":12,"title":["Cancer risk of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs among older Americans with rheumatoid arthritis"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4754-6281","authenticated-orcid":false,"given":"Shyfuddin","family":"Ahmed","sequence":"first","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute , Rockville, MD,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7791-2698","authenticated-orcid":false,"given":"Ruth M","family":"Pfeiffer","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute , Rockville, MD,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6986-8842","authenticated-orcid":false,"given":"Sarah S","family":"Jackson","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute , Rockville, MD,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9412-2871","authenticated-orcid":false,"given":"Minkyo","family":"Song","sequence":"additional","affiliation":[{"name":"Immunoepidemiology Unit, Laboratory of Epidemiology and Population Sciences, National Institute on Aging , Baltimore, MD,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4244-5417","authenticated-orcid":false,"given":"Xavier","family":"Mariette","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, H\u00f4pital Bic\u00eatre, AP-HP, F\u00e9d\u00e9ration Hospitalo-Universitaire CARE (Cancer and Autoimmunity Relationship), INSERM U1184, Universit\u00e9 Paris-Saclay , Le-Kremlin-Bic\u00eatre,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5523-1856","authenticated-orcid":false,"given":"Rapha\u00e8le","family":"Seror","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, H\u00f4pital Bic\u00eatre, AP-HP, F\u00e9d\u00e9ration Hospitalo-Universitaire CARE (Cancer and Autoimmunity Relationship), INSERM U1184, Universit\u00e9 Paris-Saclay , Le-Kremlin-Bic\u00eatre,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0203-6958","authenticated-orcid":false,"given":"Eric A","family":"Engels","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute , Rockville, MD,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,10]]},"reference":[{"key":"2025070205463588900_keaf092-B1","volume-title":"Disease modifying anti-rheumatic drugs (DMARD)","author":"Benjamin","year":"2023"},{"key":"2025070205463588900_keaf092-B2","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1111\/ajt.15495","article-title":"Epidemiologic perspectives on immunosuppressed populations and the immunosurveillance and immunocontainment of cancer","volume":"19","author":"Engels","year":"2019","journal-title":"Am J Transplant"},{"key":"2025070205463588900_keaf092-B3","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/ijc.24287","article-title":"Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies","volume":"125","author":"Anderson","year":"2009","journal-title":"Int J Cancer"},{"key":"2025070205463588900_keaf092-B4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1001\/jamaoncol.2021.5680","article-title":"Immune-mediated diseases associated with cancer risks","volume":"8","author":"He","year":"2022","journal-title":"JAMA Oncol"},{"key":"2025070205463588900_keaf092-B5","first-page":"100768","article-title":"Risk of cancer for patients with rheumatoid arthritis versus general population: a national claims database cohort study","volume":"35","author":"Beydon","year":"2023"},{"key":"2025070205463588900_keaf092-B6","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s13075-015-0728-9","article-title":"Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis","volume":"17","author":"Simon","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2025070205463588900_keaf092-B7","article-title":"Rheumatoid arthritis and cancer risk in the Million Women Study","volume":"53","author":"Yang","year":"2024","journal-title":"Int J Epidemiol"},{"key":"2025070205463588900_keaf092-B8","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.rdc.2016.09.006","article-title":"Malignancy and the risks of biologic therapies: current status","volume":"43","author":"Seror","year":"2017","journal-title":"Rheum Dis Clin North Am"},{"key":"2025070205463588900_keaf092-B9","doi-asserted-by":"crossref","first-page":"105176","DOI":"10.1016\/j.jbspin.2021.105176","article-title":"Inflammation-targeted therapies and cancer","volume":"88","author":"Kedra","year":"2021","journal-title":"Joint Bone Spine"},{"key":"2025070205463588900_keaf092-B10","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1001\/2012.jama.10857","article-title":"Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis","volume":"308","author":"Lopez-Olivo","year":"2012","journal-title":"JAMA"},{"key":"2025070205463588900_keaf092-B11","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-002139","article-title":"Risk of malignancy in rheumatoid arthritis patients initiating biologics: an historical propensity score matched cohort study within the French nationwide healthcare database","volume":"8","author":"Seror","year":"2022","journal-title":"RMD Open"},{"key":"2025070205463588900_keaf092-B12","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1158\/1055-9965.EPI-21-0125","article-title":"Tumor necrosis factor inhibitors and the risk of cancer among older Americans with rheumatoid arthritis","volume":"30","author":"D'Arcy","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2025070205463588900_keaf092-B13","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"2025070205463588900_keaf092-B14","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1136\/ard-2022-222543","article-title":"Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial","volume":"82","author":"Curtis","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025070205463588900_keaf092-B15","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/aje\/kwr146","article-title":"Use of surveillance, epidemiology, and end results\u2014Medicare data to conduct case-control studies of cancer among the US elderly","volume":"174","author":"Engels","year":"2011","journal-title":"Am J Epidemiol"},{"key":"2025070205463588900_keaf092-B16","article-title":"Comorbidity technical report: the impact of different SEER-Medicare claims-based comorbidity indexes on predicting non-cancer mortality for cancer patients","author":"Stedman","year":"2014"},{"key":"2025070205463588900_keaf092-B17","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"2025070205463588900_keaf092-B18","first-page":"1908","article-title":"Cancers and cardiovascular diseases in patients with seropositive rheumatoid arthritis treated with JAK inhibitors, biologics and conventional synthetic DMARDs","volume":"41","author":"Ahn","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"2025070205463588900_keaf092-B19","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/rheumatology\/kead163","article-title":"Cancer risk in patients with rheumatoid arthritis treated with Janus kinase inhibitors: a nationwide Danish register-based cohort study","volume":"63","author":"Westermann","year":"2024","journal-title":"Rheumatology"},{"key":"2025070205463588900_keaf092-B20","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1093\/rheumatology\/kead079","article-title":"Comparison of risks of cancer, infection, and MACEs associated with JAK inhibitor and TNF inhibitor treatment: a multicentre cohort study","volume":"62","author":"Uchida","year":"2023","journal-title":"Rheumatology"},{"key":"2025070205463588900_keaf092-B21","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1136\/ard-2022-223636","article-title":"Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study","volume":"82","author":"Huss","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025070205463588900_keaf092-B22","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/art.42250","article-title":"Tofacitinib and risk of malignancy: results from the safety of tofacitinib in routine care patients with rheumatoid arthritis (STAR-RA) study","volume":"74","author":"Khosrow-Khavar","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2025070205463588900_keaf092-B23","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/rheumatology\/kead198","article-title":"Safety of the JAK and TNF inhibitors in rheumatoid arthritis: real world data from the Hong Kong Biologics Registry","volume":"63","author":"Mok","year":"2024","journal-title":"Rheumatology"},{"key":"2025070205463588900_keaf092-B24","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1001\/jama.2011.1592","article-title":"Spectrum of cancer risk among US solid organ transplant recipients","volume":"306","author":"Engels","year":"2011","journal-title":"JAMA"},{"key":"2025070205463588900_keaf092-B25","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0140-6736(07)61050-2","article-title":"Incidence of cancers in people with HIV\/AIDS compared with immunosuppressed transplant recipients: a meta-analysis","volume":"370","author":"Grulich","year":"2007","journal-title":"Lancet"},{"key":"2025070205463588900_keaf092-B26","doi-asserted-by":"crossref","first-page":"e700","DOI":"10.1016\/S2352-3018(22)00219-3","article-title":"Trends and risk of lung cancer among people living with HIV in the USA: a population-based registry linkage study","volume":"9","author":"Haas","year":"2022","journal-title":"Lancet HIV"},{"key":"2025070205463588900_keaf092-B27","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1093\/rheumatology\/keac710","article-title":"Janus kinase inhibitors alter NK cell phenotypes and inhibit their antitumour capacity","volume":"62","author":"Meudec","year":"2023","journal-title":"Rheumatology"},{"key":"2025070205463588900_keaf092-B28","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3892\/or.2021.8183","article-title":"Natural killer cell\u2011based immunotherapy for lung cancer: challenges and perspectives (review)","volume":"46","author":"Zeng","year":"2021","journal-title":"Oncol Rep"},{"key":"2025070205463588900_keaf092-B29","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002465","article-title":"Risk of lung cancer in rheumatoid arthritis and in relation to autoantibody positivity and smoking","volume":"8","author":"Chatzidionysiou","year":"2022","journal-title":"RMD Open"},{"key":"2025070205463588900_keaf092-B30","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1136\/ard.56.8.463","article-title":"Cigarette smoking and rheumatoid arthritis severity","volume":"56","author":"Saag","year":"1997","journal-title":"Ann Rheum Dis"},{"key":"2025070205463588900_keaf092-B31","doi-asserted-by":"crossref","first-page":"5137","DOI":"10.2174\/0929867328666201207202012","article-title":"Targeting the JAK\/STAT signaling pathway for breast cancer","volume":"28","author":"Shao","year":"2021","journal-title":"Curr Med Chem"},{"key":"2025070205463588900_keaf092-B32","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.phrs.2016.07.038","article-title":"Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases","volume":"111","author":"Roskoski","year":"2016","journal-title":"Pharmacol Res"},{"key":"2025070205463588900_keaf092-B33","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41584-024-01153-1","article-title":"JAK inhibitor selectivity: new opportunities, better drugs?","volume":"20","author":"Virtanen","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"2025070205463588900_keaf092-B34","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","article-title":"Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach","volume":"18","author":"Tanaka","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2025070205463588900_keaf092-B35","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1136\/ard.2008.097527","article-title":"Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment","volume":"68","author":"Simon","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2025070205463588900_keaf092-B36","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1093\/rheumatology\/keab570","article-title":"Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice","volume":"61","author":"Huss","year":"2022","journal-title":"Rheumatology"},{"key":"2025070205463588900_keaf092-B37","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1001\/jama.2021.1117","article-title":"Screening for lung cancer: US Preventive Services Task Force recommendation statement","volume":"325","author":"Krist","year":"2021","journal-title":"JAMA"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf092\/61820067\/keaf092.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/7\/4172\/61820067\/keaf092.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/7\/4172\/61820067\/keaf092.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T09:46:49Z","timestamp":1751449609000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/7\/4172\/8006490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,10]]},"references-count":37,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,2,10]]},"published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf092","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,2,10]]}}}